NASDAQ: UNCYUnicycive Therapeutics Inc Stock
$5.86+0.12 (+2.09%)
Updated Dec 24, 2025
UNCY Price
$5.86
Fair Value Price
$3.79
Market Cap
$125.94M
52 Week Low
$3.71
52 Week High
$68.99
P/E
-1.7x
P/B
3.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$33.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.35
Operating Cash Flow
-$30M
Beta
0.71
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
UNCY Overview
Unicycive Therapeutics Inc., a biotechnology company, develops therapies for kidney diseases in the U.S. It is developing Renazorb, a treatment for hyperphosphatemia in patients with chronic kidney disease, and UNI 494, a treatment for Acute Kidney Injury. The company was incorporated in 2016 and is headquartered in Los Altos, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine UNCY's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
UNCY
Ranked#117 of 490
Ranked#117 of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.09 | A | |
| $19.77 | A | |
| $400.69 | A |
Be the first to know about important UNCY news, forecast changes, insider trades & much more!
UNCY News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how UNCY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UNCY ($5.86) is overvalued by 54.73% relative to our estimate of its Fair Value price of $3.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
UNCY ($5.86) is not significantly undervalued (54.73%) relative to our estimate of its Fair Value price of $3.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
UNCY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more UNCY due diligence checks available for Premium users.
Valuation
UNCY fair value
Fair Value of UNCY stock based on Discounted Cash Flow (DCF)
Price
$5.86
Fair Value
$3.79
Overvalued by
54.73%
UNCY ($5.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
UNCY ($5.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
UNCY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
UNCY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.7x
Industry
144.27x
Market
44.97x
UNCY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.36x
Industry
5.43x
UNCY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
UNCY's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.0M
Profit Margin
0%
UNCY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$50.6M
Liabilities
$13.1M
Debt to equity
0.35
UNCY's short-term assets ($50.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UNCY's short-term assets ($50.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UNCY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.0M
Investing
-$2.0k
Financing
$26.3M
UNCY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UNCY vs Biotech Stocks
Unicycive Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.